信達生物(01801.HK)：達伯舒®(信迪利單抗注射液)第三季度銷售收入8億元 產品銷量保持逐季增長
格隆匯10月26日丨信達生物(01801.HK)發佈公吿，2021年第三季度，達伯舒®(信迪利單抗注射液)持續取得令人鼓舞的銷售表現，有關銷售收入約為人民幣8億元，產品銷售量保持逐季增長的良好態勢。公司欣然看到於2021年，由公司所參與的“舒心可依－患者救助項目”使得越來越多患者獲益。達伯舒®(信迪利單抗注射液)是由集團與禮來製藥共同開發，並於2019年3月成功推出。
2021年上半年，達伯舒®(信迪利單抗注射液)已獲批用於治療一線非鱗狀非小細胞肺癌、一線鱗狀非小細胞肺癌和一線肝細胞癌三項新增適應症，使得達伯舒®(信迪利單抗注射液)能夠惠及更廣泛的癌症患者羣體。同時，即使在較激烈的市場競爭環境下，公司依然持續發揮達伯舒®(信迪利單抗注射液)作為首款納入國家醫保目錄的PD-1抑制劑的先發優勢，進一步拓寬城市及醫院覆蓋以擴大市場影響、積極推廣有競爭力的綜合性市場策略，以及匹配擴張銷售推廣團隊。
2021年下半年，達伯舒®(信迪利單抗注射液)用於治療一線食管鱗癌的上市申請已獲中國藥品監督管理局受理審評，用於治療一線胃癌的三期臨牀研究以及用於表皮生長因數受體酪氨酸激酶抑制劑(“EGFR-TKI”)治療失敗的EGFR突變非鱗狀非小細胞肺癌的三期臨牀研究均已達到臨牀研究終點。公司相信達伯舒®(信迪利單抗注射液)持續令人鼓舞的銷售表現顯示出其作為抗PD-1抑制劑的高品質領先品牌在中國市場具有強大的市場潛力，以及公司作為高品質廠商的商業化能力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
